The primary objective of Sirtex is to research, develop and commercialise effective treatments for liver cancer using novel small particle technology. Sirtex has developed an innovative means of treating liver cancer. In cases where it is not possible to surgically remove the liver tumours, this product can be used to deliver targeted and Y-90 microspheres are injected with internal irradiation therapy directly to the tumour.

This new therapy is called Selective Internal Radiation Therapy also know as SIRT. This technology was developed in the 1980's in Perth, Western Australia. Many patients have been treated commercially and within a clinical trial setting all over the world (Australia, USA, Europe, Singapore, Hong Kong, New Zealand and India). The treatment started in Turkey on April 2008.

©2018 RADMED A.Ş.   Yasal Uyarı

[ ana sayfa ]  [ site haritası ]  [ İletişim ]  [ Arama ]  [ English ]